Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 198
2 121.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Caplin Point Laboratories Ltd
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
| Market Cap | P/FCFE | ||||
|---|---|---|---|---|---|
| IN |
|
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
|
159.1B INR | 69.6 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -40 845 137.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
749.7B USD | 91.7 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 2 143.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.4T DKK | 35.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
372B USD | 12.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
257.3B USD | 15.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
200.4B CHF | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
162.7B GBP | 22.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
179.9B CHF | 11.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
146B USD | -458 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.
You don't have any saved screeners yet
